(Q37857659)

24 August 2017

1 reference

title

Clinical development directions in oncolytic viral therapy (English)

1 reference

24 August 2017

1 reference

R M Eager

1

1 reference

PubMed ID

21436867

24 August 2017

J Nemunaitis

series ordinal

2

1 reference

24 August 2017

25 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

18

1 reference

24 August 2017

5

1 reference

24 August 2017

305-317

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2011.7

24 August 2017

0 references

cites work

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Regression of Burkitt's lymphoma in association with measles infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Present status of oncolytic virus studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Treatment of human cancer with mumps virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

p53 and DNA polymerase alpha compete for binding to SV40 T antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Selectively replicating viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

21 January 2018

Telomerase and cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Telomerase-specific replication-selective virotherapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Functions and mechanisms of action of the adenovirus E3 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Oncolytic herpes simplex virus vectors for cancer virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Act locally, think globally.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A viral inhibitor of peptide transporters for antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Conditionally replicating herpes vectors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

The preferential cytotoxicity of reovirus for certain transformed cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Prevalence of Reovirus‐Specific Antibodies in Young Children in Nashville, Tennessee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Viruses causing common respiratory infection in man. IV. Reoviruses and Adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Targeted gene delivery by tropism-modified adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

An oncolytic adenovirus redirected with a tumor-specific T-cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Vargula hilgendorfii luciferase: a secreted reporter enzyme for monitoring gene expression in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Small RNAs and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Cell cycle control and cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Remission of chronic lymphocytic leukemia after smallpox vaccination

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Regression of Hodgkin's disease after measles

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Multiple myeloma: report of a case showing unusual remission lasting two years following severe hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Note on the experimental use of rabies vaccine for melanomatosis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

The end of the beginning: oncolytic virotherapy achieves clinical proof-of-concept

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

New developments in the virus therapy of cancer: a historical review

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Will a twist of viral fate lead to a new cancer treatment?

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Aerosol stability of infectious and potentially infectious reovirus particles

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Analysis of promoter activity from an alpha-zein gene 5' flanking sequence in transient expression assays

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Molecular cloning and deletion of the gene encoding aspergillopepsin A from Aspergillus awamori

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.7

7 January 2021

Identifiers

DOI

10.1038/CGT.2011.7

1 reference

PubMed ID

21436867

Dimensions Publication ID

24 August 2017

0 references

1 reference

PubMed ID

21436867